Shingles is caused by the varicella zoster virus, the same virus that causes chickenpox. Shingles infection occurs when the virus reactivates decades after initial infection, and affects approximately one in three persons in the general population during their lifetime. Shingles is characterized by a localized, often severely painful cutaneous eruption that can last weeks or months, and occurs most frequently in older adults.
Shingles vaccine is licensed for adults ages 50 and older. The current recommendation, however, remains to routinely immunize adults 60 years and older with a one-time dose of shingles vaccine. The vaccine can be given to people who have already had an episode of shingles. Check with your doctor to see if the vaccine is needed or if it will be covered by individual medical insurance policies.
Source: Centers for Disease Control and Prevention
You will find below all of the resources you will need about the shingles vaccine. More will be added as they are published or released.
You also may be interested in...
Publication
3/22/2019
Due to continued high demand, additional instructions and guidance have been issued for Medical Treatment Facilities (MTFs) ordering Shingrix shingles vaccine.
Report
2/1/2019
Shingrix, a recombinant zoster vaccine, was licensed in October 2017. Early post-licensure safety monitoring findings are consistent with prelicensure clinical trial data. Serious adverse events were rare, and no unexpected patterns were detected.
Report
5/25/2018
Early monitoring indicates that vaccine provides might confuse administration procedures and storage requirements of the older Zostavax and newer Shingrix shingles vaccines.
Report
5/18/2018
The percentage of adults aged ≥60 years who ever had the shingles vaccine increased from 6.7% in 2008 to 33.4% in 2016. Women were more likely than men to have had the shingles vaccine.
Publication
5/10/2018
The purpose of this message is to provide disposition instructions on shipping delays for Shingrix (zoster recombinant, adjuvanted) vaccine.
Publication
3/27/2018
Medical treatment facilities (MTFs) may now turn in soon-to-expire Zostavax shingles vaccine to potentially receive a credit on their Prime Vendor account.
Publication
2/7/2018
Examples of proper storage, handling and reconstitution of Shingrix recombinant shingles vaccine.
Fact Sheet
2/5/2018
This information paper describes the Herpes Zoster (Shingles) disease and vaccine to prevent it.
Report
1/26/2018
Revised recommendations for use of shingles vaccines following the October 2017 approval of a new vaccine.
Policy
- Identification #: N/A
- Date: 7/25/2011
- Type: Directives
- Topics:
Shingles
Page 1 of 1
, showing items 1 - 10
You are leaving Health.mil
The appearance of hyperlinks does not constitute endorsement by the Department of Defense of non-U.S. Government sites or the information, products, or services contained therein. Although the Defense Health Agency may or may not use these sites as additional distribution channels for Department of Defense information, it does not exercise editorial control over all of the information that you may find at these locations. Such links are provided consistent with the stated purpose of this website.
You are leaving Health.mil
View the external links disclaimer.
Last Updated: May 05, 2023